Clinical Trial Update: A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 study of M2951 in relapsing-remitting multiple sclerosis was terminated, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• M2951

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2021-02-05